We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Bristol Myers Squibb (BMS) has exercised an option under a neuroscience research and development partnership, to obtain an exclusive US licence to Prothena’s anti-tau antibody, PRX005.
The system, called CRISPR-LNPs, carries a genetic messenger (messenger RNA), which encodes for the CRISPR enzyme Cas9 that acts as molecular scissors that cut the cells’ DNA.
Israel-based Tel Aviv University (TAU)’s technology transfer company Ramot has entered a research and licence agreement with Swiss-based biopharmaceutical company Neovii to develop a vaccine against Covid-19.
Research into detecting tau proteins in the brains of Alzheimer’s patients has shown that a specific tracer could detect and measure the protein levels…